Who is the host of The Lancet Infectious Diseases in conversation with?

The Lancet Infectious Diseases in conversation with is hosted by Unknown Host. The show is categorised under health (fitness) and has published 23 episodes.

How many episodes does The Lancet Infectious Diseases in conversation with have?

The Lancet Infectious Diseases in conversation with has published 23 episodes.

What topics does The Lancet Infectious Diseases in conversation with cover?

The Lancet Infectious Diseases in conversation with regularly covers health, fitness, medicine. It sits in the health category, with a fitness focus.

Is it hard to get booked on The Lancet Infectious Diseases in conversation with?

The Lancet Infectious Diseases in conversation with is accessible for guests with genuine health expertise. A personalised, episode-aware pitch will still outperform a generic one every time.

Is The Lancet Infectious Diseases in conversation with currently accepting guest pitches?

The Lancet Infectious Diseases in conversation with hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.

What guest credentials does The Lancet Infectious Diseases in conversation with typically look for?

Our data rates The Lancet Infectious Diseases in conversation with's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.

health

The Lancet Infectious Diseases in conversation with

Q: How do I pitch The Lancet Infectious Diseases in conversation with as a podcast guest?

To pitch The Lancet Infectious Diseases in conversation with, visit https://lancetid.podbean.com for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent health coverage.

Q: How long are The Lancet Infectious Diseases in conversation with episodes?

Episodes of The Lancet Infectious Diseases in conversation with average 23 minutes. a focused format where a clear narrative arc and tight preparation matter most.

Hosted by Unknown Host · health · EN · 23 episodes

Audience: 3

Apple Podcasts Website

About this Podcast:

The editorial team of The Lancet Infectious Diseases , in conversation with the journal’s authors, explores their latest research and its impact on people’s health, healthcare, and health policy. An audio companion to the journal, this podcast covers a broad range of topics, from mpox diagnostics in Africa, long COVID, adaptive trials in infectious diseases, tuberculosis drug development, and more.

Pitch Analysis

Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.

Contact path

Public web form

Booking probability

29%

Guest openness

Selective

80/100

Required Score

Signup to Generate a Pitch

What is The Lancet Infectious Diseases in conversation with?

The Lancet Infectious Diseases in conversation with is a health podcast hosted by Unknown Host, with 23 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

About the host

Unknown Host hosts The Lancet Infectious Diseases in conversation with, a health show with 23 episodes published.

Host email not verified for this showSign in to unlock →

Recent episodes

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

Episode #4
Fernando Tortosa and Ariel Izcovich on hantavirus infections
Jul 24, 202624 min
Fernando Tortosa and Ariel Izcovich discuss various aspects of hantavirus infections with a focus on the situation in Argentina, including transmission, epidemiology, clinical course, management, latest research developments, difficulties in conducting clinical trials, and future research priorities. The speakers also discuss the main findings and clinical implications of a study 'Use of tocilizumab for severe hantavirus pulmonary syndrome: a MEURI case series with contextual comparisons' they recently published in the journal. Click here to read the full article: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00285-9/abstract The Lancet Infectious Diseases in conversation with... is part of the Lancet Group podcast offering. Editorial team: editor-in-chief Ursula Hofer, deputy editor Marco De Ambrogi, and senior editors Syeda Saleha Hassan and Phoebe Hall Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering. Find the best science for better lives at lancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv
Listen Show Notes
Episode #3
Brecht Ingelbeen and Daniel Valia on a community-based antimicrobial stewardship intervention in Burkina Faso and DRC
Jun 15, 202627 min
Dr Brecht Ingelbeen and Dr Daniel Valia join Senior Editor Phoebe Hall to discuss a new trial in the journal (the CABU-EICO trial) testing a co-created behavioural intervention bundle to improve antibiotic use, patient management, and water, sanitation and hygiene in rural communities in Burkina Faso and DR Congo. They explain why the study focused on community prescribing (not hospitals), the primary endpoint was a reduction in WHO AWaRE Watch antibiotics (not overall antibiotics), and the intervention targeted all providers of antibiotics in the community, including informal vendors. Finally, they discuss the importance of designing an intervention bundle that was truly tailored to local context yet practical, sustainable, and scalable beyond the study sites. A parallel study reporting the effect of the intervention bundle on ESBL-producing Escherichia coli colonisation (a co-primary outcome of the trial) is in press at The Lancet Microbe. To read the full article: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00169-6/fulltext The Lancet Infectious Diseases in conversation with... is part of the Lancet Group podcast offering. Editorial team: editor-in-chief Ursula Hofer, deputy editor Marco De Ambrogi, and senior editors Syeda Saleha Hassan and Phoebe Hall Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering. Find the best science for better lives at lancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv
Listen Show Notes
Episode #2
Sara Tartof and Matan Yechezkel on durability of doxycycline effectiveness against syphilis, gonorrhoea, and chlamydia after implementation of post-exposure prophylaxis in southern California
May 7, 202626 minS0
Sara Tartof and Matan Yechezkel discuss a new article in The Lancet Infectious Diseases about emerging doxycycline resistance against gonorrhoea and its wider implications for the implementation of doxycycline and the prevention of bacterial sexually transmitted infections. Click here to read the full article: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00123-4/fulltext The Lancet Infectious Diseases in conversation with... is part of the Lancet Group podcast offering. Editorial team: editor-in-chief Ursula Hofer, deputy editor Marco De Ambrogi, and senior editors Syeda Saleha Hassan and Phoebe Hall Podc...
Listen Show Notes
The Lancet Infectious Diseases in conversation with
Jenny Clarke and Herve Semukunzi
Mar 9, 202621 minS0
Dr Jenny Clarke and Herve Semukunzi discuss a study they and colleagues recently published with us titled ‘Infection- and vaccine-induced mpox antibodies: validation of a combined mpox IgG ELISA during the clade 1b outbreak in Rwanda’. They also discuss the reasons for the paucity of validated serological assays for mpox, particularly in outbreak regions where they are most urgently needed. Click here to read the full article: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00006-X/fulltext Continue this conversation on social! Follow us today at... https...
Listen Show Notes
The Lancet Infectious Diseases in conversation with
Julia Moore Vogel and Danilo Buonsenso on long COVID
Dec 19, 202528 minS0
Dr Julia Moore Vogel and Dr Danilo Buonsenso discuss various aspects of long COVID including epidemiology, pathophysiology, underlying mechanisms, management, latest research developments, difficulties in conducting clinical trials, and future research priorities. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv The Lancet Infectious Diseases in conversation with... is part of the Lancet Group podcast offering. Editorial team: editor-in-chief Ursula Hofer, deputy editor Marco De Ambrogi, and...
Listen Show Notes

Guest Appearances

Recent guests on The Lancet Infectious Diseases in conversation with. Study who booked and why before you pitch.

Alex Howard

editorial director, The Dark Room Podcast

Catherine Liu

Virtue Hoarders: The Case Against the Professional Managerial Class, Fred Hutchinson Cancer Center

Paul Chapman

Noodle Photography

Advertisers on this show

Sponsor detection runs nightly. Check back soon.

Best industries to pitch The Lancet Infectious Diseases in conversation with for

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

healthstrong

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.

Podcasts like The Lancet Infectious Diseases in conversation with

All podcasts More health Top in US Top 100 by Booking Probability Booking Probability Index How scoring works How to get on podcasts

Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.

FAQs

Every question we get asked before
someone starts their trial.

If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.

What is the difference between Founder Solo and Founder Pro?

Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.

How do agency tiers work?

Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.

What is a talent profile?

A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.

Can I switch plans later?

Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.

Do you offer a free trial?

Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.

What happens if I cancel?

You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.

Is the 20% annual discount automatic?

Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.

What if I have more than 50 profiles or 20 clients?

That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.

Every question we get asked before
someone starts their trial.

If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.

What is the difference between Founder Solo and Founder Pro?

How do agency tiers work?

What is a talent profile?

Can I switch plans later?

Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.

Do you offer a free trial?

Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.

What happens if I cancel?

You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.

Is the 20% annual discount automatic?

Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.

What if I have more than 50 profiles or 20 clients?

That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.

The Lancet Infectious Diseases in conversation with

About this Podcast:

Pitch Analysis

What is The Lancet Infectious Diseases in conversation with?

About the host

Recent episodes

Fernando Tortosa and Ariel Izcovich on hantavirus infections

Brecht Ingelbeen and Daniel Valia on a community-based antimicrobial stewardship intervention in Burkina Faso and DRC

Sara Tartof and Matan Yechezkel on durability of doxycycline effectiveness against syphilis, gonorrhoea, and chlamydia after implementation of post-exposure prophylaxis in southern California

Jenny Clarke and Herve Semukunzi

Julia Moore Vogel and Danilo Buonsenso on long COVID

Guest Appearances

Alex Howard

Catherine Liu

Paul Chapman

Advertisers on this show

Best industries to pitch The Lancet Infectious Diseases in conversation with for

Podcasts like The Lancet Infectious Diseases in conversation with

Every question we get asked beforesomeone starts their trial.

The Lancet Infectious Diseases in conversation with

About this Podcast:

Pitch Analysis

What is The Lancet Infectious Diseases in conversation with?

About the host

Recent episodes

Fernando Tortosa and Ariel Izcovich on hantavirus infections

Brecht Ingelbeen and Daniel Valia on a community-based antimicrobial stewardship intervention in Burkina Faso and DRC

Sara Tartof and Matan Yechezkel on durability of doxycycline effectiveness against syphilis, gonorrhoea, and chlamydia after implementation of post-exposure prophylaxis in southern California

Jenny Clarke and Herve Semukunzi

Julia Moore Vogel and Danilo Buonsenso on long COVID

Guest Appearances

Alex Howard

Catherine Liu

Paul Chapman

Advertisers on this show

Best industries to pitch The Lancet Infectious Diseases in conversation with for

Podcasts like The Lancet Infectious Diseases in conversation with

Every question we get asked beforesomeone starts their trial.

Every question we get asked before
someone starts their trial.

Every question we get asked before
someone starts their trial.